@Article{096504016X14801968368898,
AUTHOR = {Jing Zheng, Jianya Zhou, Yanping Zhu, Qian Shen, Jianying Zhou},
TITLE = {Significant Radiologic Response of Pancreatic Metastasis After Targeted  Therapy of Ceritinib (LDK378) for <i>ALK</i>-Rearranged Lung  Adenocarcinoma Presenting With Hyperglycemia},
JOURNAL = {Oncology Research},
VOLUME = {25},
YEAR = {2017},
NUMBER = {4},
PAGES = {545--550},
URL = {http://www.techscience.com/or/v25n4/56835},
ISSN = {1555-3906},
ABSTRACT = {Pancreatic metastasis from non-small cell lung cancer (NSCLC) is usually asymptomatic or presents with 
abdominal pain, acute pancreatitis, or jaundice. A lung primary is associated with worse survival compared to 
pancreatic metastases from other organs. Surgical treatment of solitary metastasis to the pancreas from NSCLC 
has been reviewed in several studies, one of which had a notable disease-free interval. To our knowledge, there 
are no prior reports of targeted therapy of pancreatic metastasis of NSCLC followed by a significant response. 
Herein we report the case of a 31-year-old female with a solitary pancreatic metastasis from <i>ALK</i>-rearranged 
lung adenocarcinoma despite treatment with chemotherapy and crizotinib; she presented with symptoms of 
hyperglycemia. Targeted therapy with ceritinib (LDK378) led to symptomatic improvement and a significant 
radiologic response in the lung and pancreas, but not in the brain.},
DOI = {10.3727/096504016X14801968368898}
}